News

As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral

The company, through its new drug application (NDA), has been seeking FDA approval for selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET

In this connection, Accenture will use Google Cloud as the cloud technology provider for its INTIENT life sciences industry platform. The new, multi-year partnership will see Google’s cloud

The MAA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with

The study, part of the TRuE-AD clinical trial program, met its primary endpoint. Significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment

Achillion is mainly focused on the advancement of its oral small molecule complement inhibitors into late-stage development and commercialisation. The deal adds Alexion’s product portfolio with two clinical-stage

The deals are being carried out to help in facilitating the closing of the previously announced $63bn acquisition of Allergan by AbbVie. Brazikumab is an investigational IL-23 inhibitor,

In patients on stable background PAH-specific therapies, sotatercept demonstrated a statistically significant reduction in pulmonary vascular resistance (PVR), the trial’s primary endpoint, at week 24 versus placebo. The

DIFICID is a macrolide antibacterial medicine indicated in adults and pediatric patients aged 6 months and older for treatment of CDAD. To reduce the development of drug-resistant bacteria